Table 5.
Summary of the emerging device use for mitochondrial disease
| Device | Mechanism | Condition treated | Study design | N | Most recent update/publication | Status/results | Trial ID/reference |
|---|---|---|---|---|---|---|---|
| Near-infrared light-emitting diode | Increases expression of cytochrome c oxidase, reducing mitochondrial toxicity | LHON | Open-label clinical trial | 4 | 2014 | Terminated | NCT01389817 |
|
Transcranial direct current stimulation (tDCS) - |
Neuromodulation |
POLG‐related mitochondrial epilepsy - |
Case report | 1 | 2018 | Efficacious in treating refractory focal motor seizures | [126] |
| Case report | 1 | 2019 | No statistically or clinically significant reduction of seizures | [127] |
LHON Leber's hereditary optic neuropathy, POLG DNA polymerase gamma, catalytic subunit